[4-[2-[(16E,24E,26E,28E)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯内酰胺
• 英文名称: [4-[2-[(16E,24E,26E,28E)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
• 化学式: C₅₆H₈₇NO₁₆
• 分子量: 1030.3
• InChiKey: CBPNZQVSJQDFBE-WEDGMEQVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  73
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  242
• 氢给体数：
  4
• 氢受体数：
  16

文献信息

• PROCESS FOR THE PREPARATION OF TEMSIROLIMUS AND ITS INTERMEDIATES
  申请人：Gupta Nitin

  公开号：US20110184167A1

  公开（公告）日：2011-07-28

  Novel intermediates, process for their preparation and their use in the preparation of therapeutically effective antineoplastic agents, in particular Temsirolimus of formula (I).

  新型中间体，其制备方法及其在制备具有治疗效果的抗肿瘤药物中的应用，特别是化学式（I）的坦索利莫司。
• ANTI-IGF1R
  申请人：Wang Yan

  公开号：US20110014117A1

  公开（公告）日：2011-01-20

  The present invention relates in part to anti-IGF1R antibodies and antigen-binding compositions thereof along with methods of use thereof. For example, methods of treating medical disorders such as cancer are covered.

  本发明部分涉及抗IGF1R抗体及其抗原结合组成物，以及其使用方法。例如，涵盖了治疗癌症等医学疾病的方法。
• FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING
  申请人：Ramachandra Sumant

  公开号：US20110097340A1

  公开（公告）日：2011-04-28

  Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
• STABLE PHARMACEUTICAL COMPOSITIONS OF RAPAMYCIN ESTERS
  申请人：Khattar Dhiraj

  公开号：US20110301189A1

  公开（公告）日：2011-12-08

  A stable pharmaceutical compositions of Rapamycin Esters, in particular Rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid that is free of antioxidants and a process of preparing the same.
• TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF
  申请人：Ballabio Andrea

  公开号：US20140038920A1

  公开（公告）日：2014-02-06

  The invention refers to TFEB phosphorylation inhibitors. Such molecules have a therapeutic applicability in all disorders that need induction of the cell authophagic/lysosomal system, such as lysosomal storage disorders, neurodegenerative diseases, hepatic diseases, muscle diseases and metabolic diseases.